FindTrial
Sign In

Tumor Tissue Collection

PROCEDURE5 trials

Sponsors

Medical University of Vienna, Memorial Sloan Kettering Cancer Center, Merck Sharp & Dohme LLC, University of California, San Francisco, Fondazione Policlinico Universitario Agostino Gemelli IRCCS

Conditions

Breast NeoplasmsCarcinoma, Non-Small-Cell LungColorectal NeoplasmsCutaneous Squamous Cell Carcinoma (CSCC)Endocrine Gland NeoplasmsLung NeoplasmsMedulloblastomaNeoplasms of the Female Genitalia

Unknown Phase

Establishment of a Tumor Bank for Tissue Samples
RecruitingNCT01789229
Medical University of ViennaBreast Neoplasms, Colorectal Neoplasms, Endocrine Gland Neoplasms +3
Start: 2003-09-30End: 2026-12-31Target: 10000Updated: 2023-03-23
A Study of Blood Based Biomarkers for Pancreas Adenocarcinoma
RecruitingNCT03334708
Memorial Sloan Kettering Cancer CenterPancreatic Cancer, Pancreatic Cyst, Pancreatic Diseases +1
Start: 2017-10-30End: 2026-10-30Target: 120Updated: 2026-07-10
KEYMAKER-U01 Umbrella Master Study: Studies of Investigational Agents With Either Pembrolizumab (MK-3475) Alone or With Pembrolizumab PLUS Chemotherapy in Participants With Non-small Cell Lung Cancer (NSCLC) (MK-3475-U01/KEYMAKER-U01)
RecruitingNCT04165798
Merck Sharp & Dohme LLCCarcinoma, Non-Small-Cell Lung
Start: 2019-12-19End: 2032-02-13Target: 1065Updated: 2026-06-23
Tumor-Informed ctDNA Testing for MRD Following Treatment of Squamous Cell Carcinoma
RecruitingNCT06606028
University of California, San FranciscoCutaneous Squamous Cell Carcinoma (CSCC), Squamous Cell Carcinoma Head and Neck Cancer (HNSCC), Squamous Cell Carcinoma of Head and Neck +1
Start: 2024-10-09End: 2029-12-30Target: 250Updated: 2025-12-12
Targeting MYC in High-Risk Medulloblastoma
Not yet recruitingNCT07694622
Fondazione Policlinico Universitario Agostino Gemelli IRCCSMedulloblastoma
Start: 2026-09-01End: 2029-09-01Target: 35Updated: 2026-07-10

Related Papers

Abstract CT249: Results from KEYMAKER-U01 substudy 3: a phase 2 umbrella study of pembrolizumab plus investigational agents in patients with non-small-cell lung cancer (NSCLC) previously treated with anti-PD-(L)1 therapy
Cancer Research2024-04-051 citations